Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re
The model's full reasoning — Q4 2023 call → NOWe need to determine if management conveys that the business being taken in now is of visibly higher quality than the business it is replacing, with both halves: (1) an in-versus-out quality contrast stated by management, and (2) the turnover is real, current, and already in the numbers' future. Let's examine the transcript. The call covers Vyleesi, dry eye disease, ulcerative colitis, kidney disease, erectile dysfunction combination, etc. The question is about the company's incoming business vs outgoing business. The company is a biotech with commercial product Vyleesi and pipeline. The "business" here could refer to product sales, partnerships, licensing deals, etc. Management discusses Vyleesi growth, but that's not a contrast of incoming vs outgoing quality. They talk about re-licensing U.S. rights, but that's a potential transaction, not yet done. They mention partnerships with UpScriptHealth, Fosun, Kwangdong, but those are not described as higher quality than existing business. They also discuss new programs: PL9643 for dry eye, PL8177 for ulcerative colitis, PL9588 for glaucoma, and a combination for erectile dysfunction. But they don't contrast the quality of these incoming programs against existing business in terms of economics or margins. They talk about potential partnerships, but not as a present-tense reality of better business coming in. The question specifically asks: "does management convey that the business the company is TAKING IN RIGHT NOW is of visibly HIGHER QUALITY than the business it is finishing, replacing, or letting run off?" That is, is there a contrast between new incoming work and old business? For example, new contracts at better terms, or letting lower-quality business run off. In the transcript, there is no such contrast. Management talks about Vyleesi growth, but that's the same product. They talk about advancing pipeline, but that's not "business taken in" in the sense of orders or contracts. They mention potential partnerships, but those are future possibilities, not current intake. They also mention that Vyleesi net product revenue exceeds operating expenses, but that's not a contrast of quality. Thus, the answer is NO. There is no in-versus-out quality contrast stated by management. They don't describe incoming business as better than outgoing. They don't talk about letting lower-quality business run off.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| BBD | Banco Bradesco S.A. | Q3 2022 | 2022-11-09 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.